Induction of Bordetella pertussis-specific immune memory by DTPa vaccines

Vaccine

Volumn 29, Issue 18, 2011, Pages 3449-3455

  Morel, Sandra ^a   Denoël, Philippe ^a   Godfroid, Fabrice ^a   Cortvrindt, Caroline ^a   Vanderheyde, Nathalie ^a   Poolman, Jan ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

B cell memory; Bordetella pertussis; Immune memory; Immune response; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HYDROXIDE; PEDIACE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BACTERIAL IMMUNITY; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MEMORY CELL; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; PLASMA CELLS; WHOOPING COUGH;

EID: 79954652303     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.062     Document Type: Article

References (50)

1. Edwards K.M., Decker M.D. Pertussis vaccine. Vaccines 2008, 467-518. Elsevier, Philadelphia, PA. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
2. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18(2):326-382.
3. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995, 96(3):548-557.
4. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334(6):349-355.
5. Jefferson T., Rudin M., DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003, 21(17-18):2003-2014.
6. Denoël P., Godfroid F., Guiso N., Hallander H., Poolman J. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 2005, 23(46-47):5333-5341.
7. Poolman J. Comparison of seven licenced Pa vaccines in a mouse respiratory model. Proceedings of the 39th interscience conference on antimicrobial agents and chemotherapy, vol. 19 1999, G233.
8. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16(20):1901-1906.
9. Olin P., Hallander H.O., Gustafsson L., Reizenstein E., Storsaeter J. How to make sense of pertussis immunogenicity data. Clin Infect Dis 2001, 33(Suppl. 4):S288-S291.
10. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(20):1907-1916.
11. Taranger J., Trollfors B., Lagergård T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000, 181(3):1010-1013.
12. Poolman J.T., Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 2007, 6(1):47-56.
13. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G.F. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998, 132(6):983-988.
14. Salmaso S., Mastrantonio P., Wassilak S.G.F., Giuliano M., Anemona A., Giammanco A., et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II working group. Vaccine 1998, 16(13):1270-1275.
15. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24(Suppl. 5):S58-S61.
16. Guiso N., Njamkepo E., Vié le Sage F., Zepp F., Meyer C.U., Abitbol V., et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007, 25(8):1390-1397.
17. Mahon B.P., Brady M.T., Mills K.H.G. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 2000, 181(6):2087-2091.
18. Olin P., Gustafsson L., Barreto L., Hessel L., Mast T.C., Van Rie A., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21(17-18):2015-2021.
19. Carlsson RM, Gustafsson L. Pertussis surveillance in Sweden. Progress Report October 1997-September 2006, 2007. Smittskyddsinstitutets rapportserie, <> [accessed 31.01.11]. http://www.smittskyddsinstitutet.se/upload/Publikationer/SMI-rapport-2007-1%2520(version%25202).pdf.
20. Denoël P., Poolman J., Carletti G., Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine 2002, 20(19-20):2551-2555.
21. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996, 334(6):341-348.
22. Di Tommaso A., Bartalini M., Peppoloni S., Podda A., Rappuoli R., De Magistris M.T. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine 1997, 15(11):1218-1224.
23. Buisman A.M., de Rond C.G.H., Öztürk K., Ten Hulscher H.I., van Binnendijk R.S. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 2009, 28(1):179-186.
24. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(10):4969-4973.
25. Pinna D., Corti D., Jarrossay D., Sallusto F., Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol 2009, 39(5):1260-1270.
26. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357(19):1903-1915.
27. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24(5):572-577.
28. DiLillo D.J., Hamaguchi Y., Ueda Y., Yang K., Uchida J., Haas K.M., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008, 180(1):361-371.
29. Benson M.J., Elgueta R., Schpero W., Molloy M., Zhang W., Usherwood E., et al. Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med 2009, 206(9):2013-2025.
30. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298(5601):2199-2202.
31. Godfroid F., Denoël P., De Grave D., Schuerman L., Poolman J. Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses. Int J Med Microbiol 2004, 294(5):269-276.
32. Guiso N., Capiau C., Carletti G., Poolman J., Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999, 17(19):2366-2376.
33. Cattaneo L.A., Reed G.W., Haase D.H., Wills M.J., Edwards K.M. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996, 173(5):1256-1259.
34. Mink C.M., Cherry J.D., Christenson P., Lewis K., Pineda E., Shlian D., et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992, 14(2):464-471.
35. Rothstein E., Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 2005, 24(Suppl. 5):S44-S47.
36. Strebel P., Nordin J., Edwards K., Hunt J., Besser J., Burns S., et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001, 183(9):1353-1359.
37. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007, 26(4):293-299.
38. Forsyth K.D., Campins-Marti M., Caro J., Cherry J.D., Greenberg D., Guiso N., et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004, 39(12):1802-1809.
39. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006, 118(3):978-984.
40. Halperin S.A., Barreto L., Eastwood B.J., Medd L., Guasparini R., Mills E. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine 1997, 15(3):295-300.
41. Halperin S.A., King J., Law B., Mills E., Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 1999, 28(5):995-1001.
42. Barnard A., Mahon B.P., Watkins J., Redhead K., Mills K.H.G. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 1996, 87(3):372-380.
43. Redhead K., Watkins J., Barnard A., Mills K.H.G. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993, 61(8):3190-3198.
44. Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997, 65(6):2168-2174.
45. Mascart F., Hainaut M., Peltier A., Verscheure V., Levy J., Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007, 25(2):391-398.
46. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93(1):1-10.
47. Corbel M.J., Mastrantonio P., Kreeftenberg J.G. Ad hoc working group on acellular pertussis vaccines, World Health Organisation, Geneva, 27-28 July 2000. Vaccine 2001, 20(3-4):288-291.
48. Corbel M.J., Kreeftenberg J.G., Knezevic I. WHO working group on the standardisation and control of pertussis vaccines-report of a meeting, Ferney-Voltaire, France, 6-7 May 2003. Vaccine 2004, 22(3-4):293-300.
49. Zinke M., Kappes R., Kindler K., Paulus-Koschik A., Goering U., Disselhoff J., et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccine 2009, 5(9):592-598.
50. Blanchard Rohner G., Snape M.D., Kelly D.F., John T., Morant A., Yu L.-M., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008, 180(4):2165-2173.